22-08-2019
STALICLA announces completion of pre-IND meeting with FDA on STP1 for subgroup of patients with Autism Spectrum Disorder (ASD)
17-03-2019
Stalicla, uma startup genebrina, recorre a algoritmos para definir perfil biológico de cada grupo de autistas e, assim, identificar fármacos mais eficazes. O ensaio clínico do primeiro pacote terapêutico da empresa aguarda luz verde da agência reguladora de medicamentos dos Estados Unidos.
27-02-2019
STALICLA SA’s CEO Lynn Durham joined a panel of leading industry experts at the SACHS European Life Sciences CEO Forum on February 25th-26th, 2019 in Zurich, Switzerland. The ‘Neuroscience BD&L’ panel which Lynn was part of, took place at 11:20am Monday 25th.
